dpp-4 inhibitor with glp-1 receptor agonist combination not recommended ada Frontiers The Role of DPP-4 Inhibitors

Anwar et al

Castejon et al

In addition, it is necessary to clarify the pharmacodynamic material basis of compound preparations through spectrum-effect relationship analysis, systematically conduct pharmacokinetic studies to optimize absorption and distribution characteristics, and utilize nanotechnology, such as metal-organic framework carriers and exosome biomimetic delivery, to develop intelligent delivery systems targeting pulmonary blood vessels and immune cells

New technologies are allowing selective identification of subsets or sub-states of reactive astrocytes, and have identified a role for a potentially therapeutically targetable mechanism that limits XBP1-driven pathogenic astrocyte responses